Overview
- Structure and mechanism of eukaryotic type IIA topoisomerases
- DNA topoisomerase I and illegitimate recombination
- Mechanism regulating cellular responses to DNA topoisomerase I-targeted agents
Part of the book series: Cancer Drug Discovery and Development (CDD&D)
Access this book
Tax calculation will be finalised at checkout
Other ways to access
Table of contents (19 chapters)
-
Front Matter
Keywords
About this book
DNA topoisomerases represent an essential family of DNA processing enzymes and a large number of topoisomerase inhibitors are used clinically for the treatment of various human cancers. Novels drugs are in clinical development both against type I and type II topoisomerases. The book will include basic biochemical and structural reviews for the cancer-relevant topoisomerases. It will describe how topoisomerase dysfunctions can damage the genome and increase the risk of cancers, and the involvement of topoisomerases in programmed cell death. The book will also present the various topoisomerase inhibitors in clinical use and development and their molecular and cellular mechanisms of action.
Editors and Affiliations
Bibliographic Information
Book Title: DNA Topoisomerases and Cancer
Editors: Yves Pommier
Series Title: Cancer Drug Discovery and Development
DOI: https://doi.org/10.1007/978-1-4614-0323-4
Publisher: Humana New York, NY
eBook Packages: Medicine, Medicine (R0)
Copyright Information: Springer Science+Business Media, LLC 2012
Hardcover ISBN: 978-1-4614-0322-7Published: 20 September 2011
Softcover ISBN: 978-1-4614-2963-0Published: 25 October 2013
eBook ISBN: 978-1-4614-0323-4Published: 21 September 2011
Series ISSN: 2196-9906
Series E-ISSN: 2196-9914
Edition Number: 1
Number of Pages: XI, 443
Number of Illustrations: 16 b/w illustrations, 49 illustrations in colour
Topics: Cancer Research, Pharmacology/Toxicology